SLC16A1 and renal cell carcinoma: While there are no other agents currently in clinical development specifically aimed at GPR65, there are studies exploring the therapeutic potential of investigational medicinal products targeting other components of the acidic TME—such as CA9 and MCT—in RCC [136,137,138,139,140,141,142,143,144].